The latest studies for the first-line treatment of HR+/HER2− advanced breast cancer (ABC) based on these CDK4/6 inhibitors include the PALOMA series [6,7,8], the MONARCH series [5], the MONALEESA series [9], and the DAWNA series [10], most of which have achieved positive results. This evidence concerns the gene CDK4 and breast carcinoma.